As a potent and selective FLT3 inhibitor for AML, Quizartinib (AC220) is a potent and selective second‐generation class III receptor TKI, highly effective against FLT3‐ITD mutated AML cells has been primarily evaluated in relapsed and refractory AML settings [47, 48]. This evidence concerns the gene FLT3 and acute myeloid leukemia.